MDWD: Phase III VALUE trial and manufacturing expansion drive growth, with strong competitive positioning
Key growth drivers include the phase III VALUE trial for EscharEx, ongoing expansion of manufacturing capacity, and steady revenue from NexoBrid. Competitive positioning is strong, with faster debridement than legacy products and additional indications planned.Based on MediWound Ltd. [MDWD] H.C. Wa…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.